Stephen Willey's questions to Abeona Therapeutics Inc (ABEO) leadership • Q1 2025
Question
Stephen Willey from Stifel questioned the expected patient throughput at qualified treatment centers (QTCs), both at launch and at steady-state, and asked how the PRV sale impacts the prioritization of the company's early-stage pipeline.
Answer
Chief Commercial Officer Dr. Madhav Vasanthavada stated that physicians at potential QTCs are comfortable with a throughput of two patients per month per site, with some institutions indicating capacity for up to four. CEO Dr. Vish Seshadri addressed the pipeline, confirming that the RS1 ophthalmology program remains on track for in-human studies in the second half of 2026, a cadence that fits well with the ZEVASKYN commercial ramp. He noted the PRV proceeds support this without accelerating timelines that are dictated by scientific processes.